Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
48-week open-label extension study of elvucitabine plus background antiretroviral therapy in HIV-1-infected subjects previously treated in ACH443-014A
2006-006194-25Phase 2Completed
- Sponsor
- Achillion Pharmaceuticals
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elvucitabine in Human immunodeficiency virus infection type 1, sponsored by Achillion Pharmaceuticals. Primary endpoint: Safety. Started Apr 2007; status: completed.
02
Drugs
elvucitabine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2006-006194-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006194-25.